Wolfel E E, Selland M A, Cymerman A, Brooks G A, Butterfield G E, Mazzeo R S, Grover R F, Reeves J T
Cardiovascular Pulmonary Research Laboratory, Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
J Appl Physiol (1985). 1998 Sep;85(3):1092-102. doi: 10.1152/jappl.1998.85.3.1092.
Whole body O2 uptake (VO2) during maximal and submaximal exercise has been shown to be preserved in the setting of beta-adrenergic blockade at high altitude, despite marked reductions in heart rate during exercise. An increase in stroke volume at high altitude has been suggested as the mechanism that preserves systemic O2 delivery (blood flow x arterial O2 content) and thereby maintains VO2 at sea-level values. To test this hypothesis, we studied the effects of nonselective beta-adrenergic blockade on submaximal exercise performance in 11 normal men (26 +/- 1 yr) at sea level and on arrival and after 21 days at 4,300 m. Six subjects received propranolol (240 mg/day), and five subjects received placebo. At sea level, during submaximal exercise, cardiac output and O2 delivery were significantly lower in propranolol- than in placebo-treated subjects. Increases in stroke volume and O2 extraction were responsible for the maintenance of VO2. At 4,300 m, beta-adrenergic blockade had no significant effect on VO2, ventilation, alveolar PO2, and arterial blood gases during submaximal exercise. Despite increases in stroke volume, cardiac output and thereby O2 delivery were still reduced in propranolol-treated subjects compared with subjects treated with placebo. Further reductions in already low levels of mixed venous O2 saturation were responsible for the maintenance of VO2 on arrival and after 21 days at 4,300 m in propranolol-treated subjects. Despite similar workloads and VO2, propranolol-treated subjects exercised at greater perceived intensity than subjects given placebo at 4,300 m. The values for mixed venous O2 saturation during submaximal exercise in propranolol-treated subjects at 4,300 m approached those reported at simulated altitudes >8,000 m. Thus beta-adrenergic blockade at 4,300 m results in significant reduction in O2 delivery during submaximal exercise due to incomplete compensation by stroke volume for the reduction in exercise heart rate. Total body VO2 is maintained at a constant level by an interaction between mixed venous O2 saturation, the arterial O2-carrying capacity, and hemodynamics during exercise with acute and chronic hypoxia.
在高海拔地区进行最大运动和次最大运动时,尽管运动期间心率显著降低,但全身氧气摄取量(VO₂)在β-肾上腺素能阻滞剂作用下仍能保持。有人提出,高海拔地区每搏输出量的增加是维持全身氧气输送(血流量×动脉血氧含量)从而使VO₂维持在海平面水平的机制。为验证这一假设,我们研究了非选择性β-肾上腺素能阻滞剂对11名正常男性(26±1岁)在海平面、抵达4300米时以及在4300米停留21天后次最大运动表现的影响。6名受试者服用普萘洛尔(240毫克/天),5名受试者服用安慰剂。在海平面进行次最大运动时,服用普萘洛尔的受试者的心输出量和氧气输送量显著低于服用安慰剂的受试者。每搏输出量和氧摄取量的增加维持了VO₂。在4300米处,β-肾上腺素能阻滞剂对次最大运动期间的VO₂、通气、肺泡PO₂和动脉血气无显著影响。尽管每搏输出量增加,但与服用安慰剂的受试者相比,服用普萘洛尔的受试者的心输出量以及由此导致的氧气输送量仍降低。在抵达4300米时以及在4300米停留21天后,服用普萘洛尔的受试者混合静脉血氧饱和度本就已低,其进一步降低是维持VO₂的原因。尽管工作量和VO₂相似,但在4300米时,服用普萘洛尔的受试者比服用安慰剂的受试者感觉运动强度更大。服用普萘洛尔的受试者在4300米进行次最大运动时的混合静脉血氧饱和度值接近在模拟海拔>8000米时报告的值。因此,在4300米处,β-肾上腺素能阻滞剂导致次最大运动期间氧气输送量显著降低,原因是每搏输出量对运动心率降低的补偿不完全。在急性和慢性缺氧运动期间,全身VO₂通过混合静脉血氧饱和度、动脉携氧能力和血流动力学之间的相互作用维持在恒定水平。